Dermatology Allergy Strong — EAACI 2022 / NICE TA339
Urticaria Activity Score (UAS7)
7-day urticaria activity score assessing wheals and pruritus, used to guide antihistamine dosing and omalizumab eligibility in chronic spontaneous urticaria (CSU).
References
- Zuberbier T et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2022.
- NICE TA339. Omalizumab for treating chronic spontaneous urticaria. 2015.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Omalizumab (Dermatology — Chronic Urticaria) · Anti-IgE Monoclonal Antibody
- Promethazine · First-Generation Antihistamine — Burns Pruritus / Sedation
- Pindolol · Non-selective β-blocker (with intrinsic sympathomimetic activity)
- Cyproheptadine · Antidote / Antihistamine
- Cetirizine hydrochloride · Non-sedating H1 antihistamine
- Chlorphenamine maleate · Sedating H1 antihistamine
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.